Bicara Therapeutics Inc.
BCAXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Bicara Therapeutics Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 10, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Bicara Therapeutics Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-09 · Mazumdar Claire: Larger than 59 of the 61 other insider sales of Common Stock on file. SEC filing
- 2025-11-24 · Mazumdar Claire: Larger than 60 of the 61 other insider sales of Common Stock on file. SEC filing
- 2025-10-16 · Mazumdar Claire: Larger than 56 of the 61 other insider sales of Common Stock on file. SEC filing
- 2025-10-06 · Cohlhepp Ryan: Larger than 55 of the 61 other insider sales of Common Stock on file. SEC filing
- 2025-09-29 · Meisner Lara: Larger than 58 of the 61 other insider sales of Common Stock on file. SEC filing
- 2025-03-14 · Meisner Lara: Larger than all 61 other insider sales of Common Stock on file. SEC filing
- 2025-03-14 · Meisner Lara: Larger than 57 of the 61 other insider sales of Common Stock on file. SEC filing
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-21 | Hyep Ivan · Chief Financial Officer | Common Stock | S — Open market or private sale | −9,200 | 20.42 | SEC filing |
| 2026-05-18 | Mazumdar Claire · Chief Executive Officer | Common Stock | S — Open market or private sale | −12,022 | 19.96 | SEC filing |
| 2026-05-18 | Mazumdar Claire · Chief Executive Officer | Common Stock | S — Open market or private sale | −2,978 | 20.35 | SEC filing |
| 2026-05-15 | Cohlhepp Ryan · President and COO | Common Stock | S — Open market or private sale | −4,500 | 20.29 | SEC filing |
| 2026-05-15 | Cohlhepp Ryan · President and COO | Common Stock | S — Open market or private sale | −8,000 | 20.29 | SEC filing |
| 2026-04-27 | Raben David · Chief Medical Officer | Common Stock | S — Open market or private sale | −5,500 | 22.88 | SEC filing |
| 2026-04-21 | Hyep Ivan · Chief Financial Officer | Common Stock | S — Open market or private sale | −9,200 | 23.00 | SEC filing |
| 2026-04-20 | Mazumdar Claire · Chief Executive Officer | Common Stock | S — Open market or private sale | −15,000 | 23.61 | SEC filing |
Showing 8 of 15 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-09 | Bowden Christopher · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-06-09 | Simson Jake · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-06-09 | Robertson Scott M. · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-06-09 | POWELL MICHAEL · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-06-09 | Haviland Kate · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-06-09 | RA Capital Healthcare Fund LP · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-06-09 | Mazumdar-Shaw Kiran · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +19,475 | SEC filing |
| 2026-05-21 | Hyep Ivan · Chief Financial Officer | Common Stock | M — Exercise or conversion of derivative security | +9,200 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.